Alli
Alli
Alli (Orlistat)Application
According to Physician Desk Reference (2003), Alli is shown for adiposity treatment, including reduction and maintenance of mass of a body, in a combination to a hypohigh-calorie diet. Alli also is shown for reduction of risk of a repeated increase of mass of a body after its initial depression. Alli is shown patients with adiposity at an index of mass of a body (its calculation - see "Special indicatings") 30 kg/m2 or 27 kg/m2 in the presence of other risk factors (a diabetes, an arterial hypertensia).
Contraindications
Hypersensitivity, a cholestasia.
Restrictions to application
Children's age (safety and efficiency are not established), a hyperoxaluria in the anamnesis, a nephrolithiasis (calcium oxalic stones).
Application at pregnancy and feeding by a breast: Adequate well controllable Alli researches at pregnant women it was not spent. As data of tests for animals not always can predetermine response at the person, Alli is not recommended to apply during pregnancy. It is not known, whether cosecretes Alli in thoracal milk, it is not necessary to apply it at feeding women.
Side effects
According to double blind, platsebo-supervised clinical tests, at the patients accepting Alli 120 mg 3 times a day against a diet, within the first and second year of observation it is the most frequent (with frequency of ?5 %) side effects from the party GASTROINTESTINAL TRACT which reflected the mechanism of action of a preparation became perceptible. Near to the name frequency of occurrence of the given by-effect on the first/second year of observation in Alli group.
From organs GASTROINTESTINAL TRACT
Oily allocation of 26,6 %/4,4 % (1,3 %/0,2 %), a meteorism and allocation of gases of 23,9 %/2,1 % (1,4 %/0,2 %), imperative desires on a defecation of 22,1 %/2,8 % (6,7 %/1,7 %), a fat/oily chair of 20,0 %/5,5 % (2,9 %/0,6 %), oily excrements of 11,9 %/2,3 % (0,8 %/0,2 %), increase of a defecation of 10,8 %/2,6 % (4,1 %/0,8 %), an incontience of a feces of 7,7 %/1,8 % (0,9 %/0,2 %).
These and other often observable collateral reactions basically were moderately severe and transient, their frequency decreased on the second year of treatment. In general the first episode of occurrence of by-effects became perceptible during 3 months from the therapy beginning. Duration of 50 % of all gastroenteric side effects bound to Alli treatment, made less than 1 week, in most cases - no more than 4 weeks. However side effects from the party GASTROINTESTINAL TRACT at some patients can develop within 6 and more months of therapy.
From nervous system and sense organs: a headache 30,6 %/N (27,6 %/N), giddiness 5,2 %/N (5,0 %/N), fatigability of 7,2 %/3,1 % (6,4 %/1,7 %), disturbance of a dream 3,9 %/N (3,3 %/N), uneasiness of 4,7 %/2,8 % (2,9 %/2,1 %), depression N/3,4 of % (N/2,5 %).
From respiratory system: infections of the top respiratory tracts of 38,1 %/26,1 % (32,8 %/25,8 %), infections of the bottom respiratory tracts 7,8 %/N (6,6 %/N), symptoms from ENTs-organs 2,0 %/N (1,6 %/N), an otitis of 4,3 %/2,9 % (3,4 %/2,5 %).
From organs GASTROINTESTINAL TRACT: an abdominal pain/discomfort 25,5 %/N (21,4 %/N), a nausea of 8,1 %/3,6 % (7,3 %/2,7 %), an infectious diarrhoeia 5,3 %/N (4,4 %/N), a pain/discomfort in a rectum of 5,2 %/3,3 % (4,0 %/1,9 %), diseases of a teeth of 4,3 %/3,1 % (2,9 %/2,3 %), diseases of gums of 4,1 %/2,0 % (2,9 %/1,5 %), vomiting 3,8 %/N (3,5 %/N).
From a locomotorium: a dorsodynia 13,9 %/N (12,1 %/N), a pain in bottom extremities N/10,8 of % (N/10,3 %), an arthritis 5,4 %/N (4,8 %/N), disturbance of function of joints 2,3 %/N (2,2 %/N), tendinitis N/2,0 of % (N/1,9 %).
From integuments: an eruption 4,3 %/N (4,0 %/N), a xeroderma 2,1 %/N (1,4 %/N).
The other: the flu 39,7 %/N (36,2 %/N), has swelled stop N/2,8 of % (N/1,9 %).
There are rare reports on hypersensitivity reactions to Alli, including an itch, an eruption, an urticaria, a Quincke's disease and an anaphylaxis.
Interaction
On preliminary data, at simultaneous Alli application and cyclosporine level of the last in plasma goes down. Alli reduces an absorption of beta carotin containing in alimentary additives, on 30 % and inhibits a vitamin E absorption (in the form of acetate tocopherol) approximately on 60 %.Alli Influence on an absorption of vitamins D, A, containing in additives, for today is not known.
Overdosage
Unitary reception 800 mg of Alli or its multiple dose in a dose to 400 mg 3 times a day within 15 days people with normal mass of a body and with adiposity was not accompanied by significant by-effects.
If the appreciable overdosage of Alli is taped, it is necessary to observe of a condition of the patient during 24 h.
Way of application and dose
Inside, with each basic food intake, containing Adepses, during meal or not later than through 1 h after meal, on 120 mg 3 times a day. The Alli reception admission if food intake or nutrition have been passed is supposed did not contain some Adepses.
As vitamin K absorption at Alli receptioncan decrease, at the patients receiving Alli against long constant reception of warfarin, it is necessary to supervise parametres of coagulation of blood attentively.
Buy Alli online
Here you can order Alli online, just click the link below.
$1.78
